Comparing two types of anesthesia for esophageal cancer surgery
Official title: Total IntraVenous AnesthesIa and ReCurrence-free Survival AfTer EsOphageal CanceR SurgerY
Run by The Cleveland Clinic · NCT04513808 · Data updated 2026-11-12
This study is testing whether a new type of anesthesia can help people with esophageal cancer have better recovery and fewer chances of their cancer coming back after surgery.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 1614 (estimated) |
| Sponsor | The Cleveland Clinic Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | August 15, 2020 |
| Main results expected | December 2026 |
| Study ends | December 2027 |
| Registry record updated | September 8, 2026 |
| Trial ID | NCT04513808 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 85 with primary esophageal cancer at stages 1-3 scheduled for curative surgery.
✕Probably not a fit
Patients with previous esophageal cancer surgeries, severe systemic diseases, or contraindications to the anesthesia types will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to compare the effectiveness of propofol-based total intravenous anesthesia versus sevoflurane-based balanced general anesthesia in patients undergoing potentially curative surgery for esophageal cancer. The primary focus is on measuring recurrence-free survival rates post-surgery, with secondary goals including the speed of discharge from the ICU and hospital, as well as the quality of recovery assessed by the QoR-15 scale on postoperative day 2. Patients will be randomly assigned to one of the two anesthesia methods to evaluate these outcomes.
Why it matters
Potential benefit: If successful, this study could lead to improved survival rates and recovery experiences for patients undergoing surgery for esophageal cancer.
How similar studies have gone: Other studies have shown promising results with similar anesthesia approaches, suggesting potential benefits in surgical outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Primary esophageal cancer without known extension beyond the esophagus. (i.e. believed to be Tumor Stage 1-3). * Scheduled for potentially curative esophageal cancer surgery. * Written informed consent, including willingness to be randomized to intravenous versus volatile anesthesia. Exclusion Criteria: * Previous surgery for esophageal cancer (except diagnostic biopsies) Age \<18 or \>85 years old. * ASA Physical Status ≥4. * Any contraindication to propofol or sevoflurane. * Other cancer not believed by the attending surgeon to be in long-term remission. * Systemic disease believed by the attending surgeon to present ≥25% two- year mortality.
Where it's running
-
Shanhai Chest Hospital
Shanghai, China Recruiting
Study contacts
- Principal investigator: Yuwei Qiu, MD — Shahai Hospital
- Study coordinator: Yuwei Qiu, MD
- Email: qiuyuweixk@163.com
- Phone: 86 21 6282 1990
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PF-08098488 in adults with advanced solid tumors
This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.
-
Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.
-
MGC030 in adults with advanced solid tumors
This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
TS-104: a first-in-human, dose-escalation study for advanced solid tumors
This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.
-
First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors
This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.